Shanghai Allist Pharmaceuticals Future Growth
Future criteria checks 2/6
Shanghai Allist Pharmaceuticals is forecast to grow earnings and revenue by 5.1% and 14.9% per annum respectively while EPS is expected to grow by 5.6% per annum.
Key information
5.1%
Earnings growth rate
5.6%
EPS growth rate
Pharmaceuticals earnings growth | 18.3% |
Revenue growth rate | 14.9% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 26 Feb 2024 |
Recent future growth updates
No updates
Recent updates
Shanghai Allist Pharmaceuticals Co., Ltd. (SHSE:688578) Stock Rockets 34% As Investors Are Less Pessimistic Than Expected
Apr 30Should You Be Adding Shanghai Allist Pharmaceuticals (SHSE:688578) To Your Watchlist Today?
Apr 01Optimistic Investors Push Shanghai Allist Pharmaceuticals Co., Ltd. (SHSE:688578) Shares Up 26% But Growth Is Lacking
Mar 04Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2025 | 3,211 | 983 | N/A | N/A | 3 |
12/31/2024 | 2,754 | 796 | N/A | N/A | 1 |
3/31/2024 | 2,479 | 916 | N/A | N/A | N/A |
12/31/2023 | 2,012 | 645 | N/A | N/A | N/A |
9/30/2023 | 1,621 | 487 | 429 | 520 | N/A |
3/31/2023 | 956 | 188 | 20 | 122 | N/A |
12/31/2022 | 791 | 131 | -52 | 92 | N/A |
9/30/2022 | 560 | -63 | -199 | -26 | N/A |
6/30/2022 | 709 | 123 | -62 | 149 | N/A |
3/31/2022 | 604 | 40 | -173 | 65 | N/A |
12/31/2021 | 530 | 18 | -163 | 29 | N/A |
9/30/2021 | 488 | 29 | -139 | 38 | N/A |
6/30/2021 | 122 | -255 | -344 | -210 | N/A |
3/31/2021 | 37 | -289 | -340 | -228 | N/A |
12/31/2020 | 1 | -311 | -285 | -197 | N/A |
9/30/2020 | 1 | -354 | -414 | -291 | N/A |
3/31/2020 | 1 | -299 | N/A | N/A | N/A |
12/31/2019 | 1 | -398 | -349 | -259 | N/A |
12/31/2018 | 5 | -97 | -133 | -97 | N/A |
12/31/2017 | 8 | -39 | N/A | 10 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 688578's forecast earnings growth (5.1% per year) is above the savings rate (2.9%).
Earnings vs Market: 688578's earnings (5.1% per year) are forecast to grow slower than the CN market (24.3% per year).
High Growth Earnings: 688578's earnings are forecast to grow, but not significantly.
Revenue vs Market: 688578's revenue (14.9% per year) is forecast to grow faster than the CN market (14.6% per year).
High Growth Revenue: 688578's revenue (14.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 688578's Return on Equity is forecast to be high in 3 years time